Gavin MacBeath, Ph.D.
Chief Executive Officer
“I am excited to be working with exceptional scientists on disruptive technology that has the potential to deliver life-changing therapies to cancer patients.”
Gavin MacBeath, Ph.D., is the Chief Executive Officer at TScan Therapeutics and serves as a member of the board of directors. He has two decades of experience in academia and industry, founding companies and driving research from early-stage discovery through drug approval. Prior to joining TScan, Gavin served as the Chief Scientific Officer at Abpro, where he advanced T cell-engaging bispecific antibodies through pre-clinical development. Previously, Gavin served as Co-founder and Senior Vice President of Discovery at Merrimack Pharmaceuticals where he advanced several biologics through IND, Phase 1, and Phase 2 clinical development. Gavin began his career in academia, where he served as the first fellow at Harvard’s Bauer Center for Genomics Research, as an Assistant Professor and later Associate Professor in the Department of Chemistry & Chemical Biology at Harvard University, and as Lecturer and Principal Investigator at Harvard Medical School. Gavin received his undergraduate degree from the University of Manitoba, his Ph.D. from The Scripps Research Institute, and postdoctoral training with Dr. Stuart Schreiber at Harvard University.
When he’s away from running R&D at TScan, Gavin relaxes by running marathons and ultramarathons. Among his various races, he has completed 9 Boston Marathons, as well as the iconic Leadville LT100 race (a 100-mile trail race in the high Rocky Mountains of Colorado).